Health Care Services

Meta Health

Meta Health released FY2026 Q1 earnings on May 8, 2026 (SGT), actual revenue SGD 372K, actual EPS SGD -0.0002

Meta Health released FY2025 annual earnings on February 27, 2026 (SGT), actual revenue SGD 1.36 M, actual EPS SGD -0.0009

Meta Health released FY2025 Q4 earnings on February 27, 2026 (SGT) with actual revenue of SGD 340K and EPS of SGD -0.0001

Meta Health released FY2025 Q3 earnings on November 11, Post-Market (SGT), with actual revenue of SGD 346 K and EPS of SGD -0.0003

Meta Health released FY2025 9 Months earnings on November 11, 2025 (SGT), actual revenue SGD 1.02 M, actual EPS SGD -0.0009

Meta Health released FY2025 Q2 earnings on August 7, 2025 (SGT) with actual revenue of SGD 362K and EPS of SGD -0.0003

Meta Health released FY2025 Semi-Annual earnings on August 7, 2025 (SGT) with actual revenue of SGD 674K and EPS of SGD -0.0005

Meta Health released FY2025 Q1 earnings on May 15, 2025 (SGT) with actual revenue of SGD 320K and EPS of SGD -0.0003

Meta Health released FY2024 Annual Earnings on February 28, 2025 (SGT), with actual revenue of SGD 244.83K and EPS of SGD -0.0013

Meta Health released FY2024 Q4 earnings on February 28 (SGT), with actual revenue of 180K SGD and EPS of -0.0007 SGD

Meta Health released FY2024 Cumulative 3Q Earnings on November 13, 2024 (SGT) with Revenue of 100,000 SGD and EPS of -0.0011

Meta Health released FY2024 Q3 earnings on November 13 (SGT), actual revenue SGD 11K, actual EPS SGD -0.0003

Meta Health released FY2024 Semi-Annual earnings on August 8, 2024 (SGT), actual revenue SGD 89K, actual EPS SGD -0.0003

Meta Health released FY2024 Q1 earnings on August 8, 2024 (SGT) with actual revenue of SGD 46K and EPS of SGD -0.0009

Meta Health released FY2024 Q2 earnings on August 8, 2024 (SGT), with actual revenue of SGD 1.046M and EPS of SGD 0.0006

Meta Health released FY2023 Annual Earnings on February 29, 2024 (SGT) with actual revenue of SGD 4.613 M and EPS of SGD -0.0128

Meta Health released FY2023 Q4 earnings on February 29, 2024 (SGT), with actual revenue of SGD 152.39 K and EPS of SGD -0.0059

Meta Health released FY2023 Cumulative Q3 Earnings on February 29, 2024 (SGT) with Revenue of 4.461M SGD and EPS of -0.0045

Meta Health released FY2022 Q2 earnings on August 12 (SGT) with actual revenue of SGD 9.346M and EPS of -0.0026

CityDev MBeCW260930

SingtelMBeCW261030

Teho

DBS MB eCW260730

OCBC Bk MB eCW260930

TencentMBeCW261005

DBS MB eCW260929

BLOK

BABX

KBAB

ARKF

Singapore-based digital finance provider MetaComp has raised $35 million in two Pre-A funding rounds, with backing from Alibaba and others. The funds will expand its StableX Network for real-time cross-border settlements using stablecoins and traditional currencies. MetaComp aims to enhance AI capabilities for automated payment services and reported achieving full-year net profitability in 2025, with liquidity exceeding $100 million.

- MetaComp, a Singapore-based digital finance infrastructure provider, has raised $35 million across two Pre-A funding rounds.  
- The latest funding round was supported by Alibaba, Spark Venture, and other shareholders, with plans to expand its StableX Network for cross-border settlements.  
- The company achieved full-year net profitability in 2025 and aims to enhance its AI capabilities, addressing inefficiencies in traditional payment systems.

The Block

Meta Platforms

Amplify Transform Data Sharing ETF

BABA 2x Long Daily ETF - GraniteShares

KraneShares 2x Long BABA Daily ETF

ARK Fintech Innovation ETF

Alibaba

BABA-W

Singapore-based MetaComp raises $35 million in funding backed by Alibaba

FINX

9XDR

METU

Financial technology company MetaComp has completed a $35 million financing round in Singapore, aiming to become the Revolut of the region. This financing is supported by institutions such as Alibaba and aims to build a cross-border payment and wealth management platform. Founder Bai Bo pointed out that there are currently no large financial technology companies in ASEAN, and the potential in the institutional client market is enormous. MetaComp will combine fiat currencies and stablecoins for cross-border settlements, striving to fill the market gap

- Singapore-based fintech company MetaComp announced it has completed a $13 million pre-Series A funding round, bringing the total funding to $35 million.  
- The investment was supported by Alibaba, Spark Venture, and existing shareholders, with plans to create a cross-border payment and wealth management platform like Revolut.  
- MetaComp operates under a Major Payment Institution license, aiming for an IPO in a few years, while currently serving over 1,000 institutional clients and processing $10 billion in payments and OTC transactions last year.

Zaobao

Global X Fintech

MetaHealth R

GraniteShares 2x Long META Daily ETF

Direxion Daily Meta Bull 2x Shares

Fintech company MetaComp raises $35 million, founder: Moving towards the regional goal of Revolut | Lianhe Zaobao

BABA

MetaComp, a Singapore fintech backed by Alibaba, aims to become 'Asia's Revolut' by targeting institutional clients with faster cross-border payment solutions. The company raised $35 million in funding and focuses on building a robust infrastructure for transaction banking, leveraging stablecoins for quicker settlements. Unlike traditional banks, MetaComp holds a major payment institution license and is not seeking banking licenses. It aims to address the pain points of slow payment processing for businesses, particularly in emerging markets, while navigating regulatory challenges in China.

- MetaComp, a Singapore fintech, raised US$35 million to develop cross-border payment solutions targeting institutional clients amid geopolitical volatility.  
- The company aims to establish a comprehensive infrastructure for faster settlements, leveraging both fiat and stablecoins while ensuring compliance with regulations.  
- With plans for an initial public offering, MetaComp seeks to expand its services globally, processing US$10 billion in transactions in 2025 and managing over US$500 million in assets.

Businesstimes News

Backed by Alibaba, Singapore’s MetaComp aims to be ‘Asia’s Revolut’ for businesses

VZ2R

Meta Health Limited and 5Digital Pte. Ltd. have reached a settlement of $136,831.82 with former executives Vasanthan Metupalle and Jagannathan Padmaja Sakthi, related to ongoing bankruptcy proceedings. The payment will be made in nine tranches starting from September. This settlement follows a disputed $200,000 payable owed by 5Digital to the executives. Upon receiving the first payment, 5Digital will discontinue its bankruptcy claim against them, with no costs ordered.

Singapore Business Review

MetaHealth R1

Meta Health, 5Digital reach $136.8k settlement with former executives

Meta Health Limited has initiated legal action in Singapore’s High Court against former executives and a business associate over the Gainhealth acquisition. The company claims breaches of duties and unlawful conspiracy, seeking damages of approximately S$7.3 million. The financial impact on the current fiscal year is uncertain. Meta Health operates in the healthcare sector, providing health-related services and products, with a current market cap of S$10.56 million.

Tip Ranks

Meta Health Limited Initiates Legal Action Over Gainhealth Acquisition

Meta Health Limited has extended the deadline for its potential acquisition of 30% of Aios Bio Sciences Pte. Ltd. from February 2, 2025, to May 3, 2025. This extension, agreed upon with vendor Mr. Davin Ng, allows more time for due diligence and negotiations, reflecting the company's strategic interest in the acquisition, which could significantly impact its operations and market positioning. Meta Health Limited is based in Singapore and focuses on expanding its market presence through strategic acquisitions.

- Meta Health Limited has announced an update on its negotiations to acquire 30% of Aios Bio Sciences Pte. Ltd.  
- The initial term sheet expired on February 2, 2025, but the deadline has been extended to May 3, 2025, for further due diligence and negotiations.  
- This acquisition could significantly impact Meta Health's operations and market positioning as it seeks to expand its presence in the healthcare industry.  

Meta Health Limited Extends Deadline for Potential Acquisition of Aios Bio Sciences